Clinical trials · New York
Lung cancer clinical trials in New York
We’re tracking 276 recruiting lung cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07783477RecruitingPhase 1
Armored CAR T cells for DLL3 positive cancers
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
New York, New YorkAges 18 years+ - NCT07718672RecruitingPhase 2
New radiation technique for early-stage lung cancer
This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.
Buffalo, New YorkAges 18 years+ - NCT07701733Recruiting
Lung cancer risk study for women who never smoked
This study looks at lung cancer risk in women who have never smoked. It aims to understand why some never-smokers develop lung cancer while others don't.
Commack, New YorkAges 40–74 - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
New York, New YorkAges 18 years+ - NCT07646847Recruiting
A support program for people with cancer on immunotherapy
This study tests a program that helps people with cancer manage side effects and find resources for needs like food, transportation, or housing. It is for patients who are starting or recently started immunotherapy for certain cancers.
New York, New YorkAges 18 years+ - NCT05349227Recruiting
After-cancer digital coaching and wearable tracking outcomes study
This study tests a digital health coaching program (using phone/tablet check-ins and wearable data) to understand health and quality-of-life outcomes after cancer treatment. It may help you learn healthy habits and track progress over time.
New York, New YorkAges 18 years+ - NCT07476287RecruitingPhase 2
Study of PF08634404 plus chemo for transformed small cell lung cancer
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
Commack, New YorkAges 18 years+ - NCT07428044RecruitingPhase 2
Trastuzumab Deruxtecan for HER2-mutant lung cancer before surgery
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
New York, New YorkAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New York, New YorkAges 18 years+ - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
East White Plains, New YorkAges 18 years+ - NCT07287085Recruiting
Increasing lung cancer screening in emergency patients
This study tests a program to help emergency department patients get screened for lung cancer. If you smoke or used to smoke, the study will see if a text message reminder can help you schedule a screening test.
Rochester, New YorkAges 50–80 - NCT03290534RecruitingPhase 2
Implantable radiation sheet for early-stage lung cancer
This Phase 2 study tests whether a permanently implanted, low-dose radiation “sheet” can be used to treat certain early-stage lung cancers. It may help shrink or control tumors while delivering radiation directly at the cancer site.
New York, New YorkAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Albany, New YorkAges 18 years+ - NCT07216144Enrolling by invitation
Lung cancer screening outreach in at-risk New Yorkers
This study helps patients at Ryan Health who are at risk for lung cancer get a free lung cancer screening (a low-dose CT scan). If you're between 50 and 80, smoke or used to smoke, and haven't had this scan in the past year, you may be able to participate.
New York, New YorkAges 50–80 - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Lake Success, New YorkAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
New York, New YorkAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
New York, New YorkAges 18 years+ - NCT06869447Recruiting
Better Breathing After Lung Cancer Treatment
This study looks at breathing exercises for people who have finished treatment for early-stage lung cancer. You'll be asked to give a blood sample at home and do breathing training to see if it helps your recovery.
Buffalo, New YorkAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Syracuse, New YorkAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
New York, New YorkAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06582771RecruitingPhase 2
Testing sotorasib for untreated lung cancer with KRAS G12C mutation
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
New York, New YorkAges 18 years+
Lung cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting lung cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Memorial Sloan Kettering Westchester · 6 studies
- NYU Langone Health · 4 studies
- Roswell Park Comprehensive Cancer Center · 4 studies
- Columbia University Irving Medical Center · 3 studies
- Memorial Sloan Kettering Commack · 2 studies
- City College of New York (Data Collection AND Specimen Analysis)
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung cancer trials in other states
Common questions
- Are there lung cancer clinical trials in New York?
- Yes. We're currently tracking 276 recruiting lung cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.